Pharmokinetics of Metoprolol in Relation to Polymorphic Sparteine Oxidation

  • W. Kirch
  • E. E. Ohnhaus
  • C. Zekorn
  • M. Eichelbaum
  • H. Spahn
  • E. Mutschler
Part of the Archives of Toxicology book series (TOXICOLOGY, volume 8)

Abstract

A close correlation between the polymorphic 4-hydroxylation of debrisoquine and the pharmacokinetics of the beta-adrenoceptor antagonist metoprolol has been reported recently (Lennard et al., 1982).

Key words

Genetic Polymorphism Sparteine Metoprolol 

References

  1. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16, 183–187PubMedCrossRefGoogle Scholar
  2. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF (1982) Oxidation phenotype —a major determinant of metoprolol metabolism and response. N Engl J Med 307, 1558–1560PubMedCrossRefGoogle Scholar
  3. Schäfer M, Mutschier E (1979) Fluorimetric determination of oxprenolol in plasma by direct evaluation on thin layer chromatograms. J. Chromatogr. 164, 247–252PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • W. Kirch
    • 1
  • E. E. Ohnhaus
    • 1
  • C. Zekorn
    • 2
  • M. Eichelbaum
    • 2
  • H. Spahn
    • 3
  • E. Mutschler
    • 3
  1. 1.Medical DepartmentUniversity School of MedicineEssenGermany
  2. 2.Medical DepartmentUniversity of BonnBonnGermany
  3. 3.Pharmacology DepartmentUniversity of Frankfurt/MainFrankfurt/MainGermany

Personalised recommendations